Answers are grounded in this paper and cite their sources.
PURPOSE: mutations. EXPERIMENTAL DESIGN: , and distinguishes somatic/reversion from germline mutations with high accuracy. RESULTS: mutations under therapeutic pressure from initial PARPi exposure, which contributed to subsequent resistance to PARPi and platinum therapy. CONCLUSIONS: mutations missed by germline testing and reversion mutations that can have important treatment implications. Further research is needed to confirm clinical utility of these findings to guide precision medicine approaches for patients with advanced malignancies.
No takes yet. Share an insight, caveat, or question.
Vidula et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: